RxDoctor Payments Data

Mitchell Levy, MD

Critical Care Medicine · Providence, RINPI 1396785325

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $12,627 of the $16,827 with a category attached, or 75.0%. 7 manufacturers reported payments, led by Sanofi US Services Inc. at 37.2% of the total. Reporting peaked in 2020 at $11,127 and has fallen 91.9% since, to $900 in 2022.

$16,827in general payments, 2019–2025

Across 8 payments — averaging $2103.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$6K
  • Teva Pharmaceuticals USA, Inc.$3K
  • Pfizer$2K
  • Sanofi Pasteur Inc.$2K
  • Janssen Research & Development, LLC$2K
  • Siemens Medical Solutions USA, Inc.$900
  • plus $600 from 1 others
$180,866in research payments, 2019–2025

Across 4 payments — averaging $45,217 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$173K
  • Regeneron$8K

What the payments were for

  • Consulting fees$12,62775%
  • Speaking & faculty fees$4,20025%

General payments by program year

19
20
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few critical care medicine providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$10,464
Medicare patients
31
Services billed
55

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other critical care medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →